Objectives: The protective efficacy of an absorptive adhesion prevention product (SeprafilmⓇ) against bowel obstruction (BO) during open surgery was demonstrated in a large-scale randomized controlled clinical trial in Europe and America. However, the efficacy of Seprafilm against BO in laparoscopic surgery remains uncertain. The objective of this study was to clarify the protective efficacy of Seprafilm against BO after laparoscopic surgery for colorectal cancer. Methods: From 2009 to 2016, 1328 laparoscopic colorectal resections were performed for colorectal cancer. From 2009, Seprafilm was used for preventing BO in laparoscopic colorectal surgery. The incidence of BO and short-term results were compared between the Seprafilm and non-Seprafilm groups after propensity score matching. Results: Propensity scoring generated 270 matched patients per group for the comparisons between the Seprafilm and non-Seprafilm groups. The two groups showed no significant differences regarding patients' backgrounds. Among all patients, 73.1% (19/26) of BO occurred within 30 days after the surgery. Significantly lower incidences of all grade (2.6% vs. 7.0%; p = 0.016) and grade 2 + 3a (1.5% vs. 5.2%; p = 0.017) BO were observed in the Seprafilm group than in the non-Seprafilm group; no significant difference regarding grade 3b BO (1.1% vs. 1.9%; p = 0.476) was found. A significant difference in BO within 30 days was also noted between the two groups (1.9% vs. 5.2%, p = 0.036). There were no significant differences between the groups regarding anastomotic leakage and deep surgical site infection. Conclusions: Seprafilm was useful for preventing BO, requiring decompression therapy of the bowel, after laparoscopic colorectal surgery without increasing adverse events.
展开▼
机译:目的:在欧洲和美国的一项大规模随机对照临床试验中,证明了一种吸收性粘连预防产品(Seprafilm Ⓡ sup>)对开放手术期间肠梗阻(BO)的保护作用。然而,Seprafilm在腹腔镜手术中抗BO的疗效仍不确定。这项研究的目的是阐明腹膜镜手术后Seprafilm对大肠癌的保护作用。方法:2009年至2016年,共进行了1328例腹腔镜结肠直肠癌切除术。从2009年起,Seprafilm用于腹腔镜结直肠手术中的BO预防。倾向评分匹配后,比较Seprafilm和非Seprafilm组的BO发生率和短期结果。结果:倾向评分每组产生270名匹配患者,用于Seprafilm和非Seprafilm组之间的比较。两组在患者背景方面无明显差异。在所有患者中,手术后30天内发生了73.1%(19/26)的BO。与非Seprafilm组相比,Seprafilm组的所有等级(2.6%vs. 7.0%; p = 0.016)和2 + 3a级(1.5%vs. 5.2%; p = 0.017)的发生率均显着降低。没有发现3b级BO的显着差异(1.1%对1.9%; p = 0.476)。两组在30天内的BO差异也很明显(1.9%对5.2%,p = 0.036)。两组之间在吻合口漏和深部手术部位感染方面无显着差异。结论:Seprafilm可用于预防腹腔镜结直肠癌手术后BO,需要对肠减压治疗,而不会增加不良事件。
展开▼